Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Closed 08-11 15:00:00

24.33

+0.21

+0.87%

High24.86	Low23.88	Vol48.73M
Open23.92	D1 Closing24.12	Amplitude4.06%
Mkt Cap64.96B	Tradable Cap51.53B	Total Shares2.67B
T/O1.19B	T/O Rate2.30%	Tradable Shares2.12B
P/B1.32	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":24.33,"timestamp":1786431601000,"preClose":24.12,"halted":0,"volume":48734772,"delay":0,"changeRate":0.0087,"floatShares":2118000000,"shares":2670000000,"eps":1.3019,"marketStatus":"Closed","change":0.21,"latestTime":"08-11 15:00:00","open":23.92,"high":24.86,"low":23.88,"amount":1194000000,"amplitude":0.0406,"askPrice":24.34,"askSize":508,"bidPrice":24.33,"bidSize":492,"shortable":0,"etf":0,"ttmEps":1.3019,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1786498200000},"marketStatusCode":5,"adr":0,"adjPreClose":24.12,"symbolType":"stock","openAndCloseTimeList":[[1786411800000,1786419000000],[1786424400000,1786431600000]],"highLimit":26.53,"lowLimit":21.71,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.32,"roa":"--","peRate":18.688071,"roe":"1.78%","epsLYR":1.27,"committee":0.108371,"marketValue":64972000000,"turnoverRate":0.023,"status":0,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":17.08,"timestamp":1786435693004,"preClose":17.05,"halted":0,"volume":2688729,"delay":0,"premium":"-39.63"},"floatMarketCap":51543000000},"requestUrl":"/m/hq/s/600196","defaultTab":"news","newsList":[{"id":"2658993953","title":"Sinopharm Group Stock Slides 1.3% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993953","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658993953?lang=en_us&edition=fundamental","pubTime":"2026-08-11 16:33","pubTimestamp":1786437180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. shed 1.3% to 16.83 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.1% to 25652.82.Sinopharm Group Co. Ltd. closed 25% short of its 52-week high of HK$22.34, which the company reached Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 0.2%.Trading volume totaled 3.4 million shares, compared to the 50-day average of 6.1 million shares.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHTDY","LU0640798160.USD","BK1197","BK0188","02196","LU1115378108.SGD","BK1500","01099","BK0096","BK0060","BK0012","BK4175","BK0175","BK0028","BK0183","600196","BK1593","BK1515","BK0239","BK1191","BK0196","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658609444","title":"Fosun Pharma Secures China Approval for Two Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658609444","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658609444?lang=en_us&edition=fundamental","pubTime":"2026-08-10 10:02","pubTimestamp":1786327325,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration (NMPA) has accepeted two drug registration applications by subsidiaries of Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196), according to separate ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK1593","BK0028","BK0239","BK1515","BK0188","BK1191","600196","02196","BK0096","BK0012","BK0183","BK0060","BK0196","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123685008","title":"Fosun Pharma Launches Head-to-Head Phase 3 Clinical Trial for a First-in-Class Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1123685008","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123685008?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:21","pubTimestamp":1786105318,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA has initiated a Phase 3 clinical trial for its novel drug candidate, FXS6837, targeting patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not received prior complement...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0239","BK1191","BK0175","BK0196","02196","BK1593","BK0187","BK1515","III","BK0012","600196","BK0183","BK0060","BK0188","BK4134","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101259954","title":"Fosun Pharma's Dobutamine Hydrochloride Injection Receives NMPA Marketing Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1101259954","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101259954?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:10","pubTimestamp":1786104615,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) has announced that its controlling subsidiary, Shanghai Zhaohui Pharmaceutical Co., Ltd., has obtained drug registration approval from the National Medical Products...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0096","BK0028","BK0196","BK1191","BK0012","600196","BK0239","BK0183","02196","BK0060","BK0187","BK0175","BK1593","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657164392","title":"Shanghai Fosun Pharma - Drug Registration Application for Dobutamine Hydrochloride Injection Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2657164392","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657164392?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:04","pubTimestamp":1786104275,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN444162:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0183","02196","BK0060","BK1191","BK0187","BK0096","BK0028","BK0188","BK1593","BK0239","BK1515","BK0012","BK0196","BK0175","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657149615","title":"Sinopharm Group Stock Sheds 0.8% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2657149615","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657149615?lang=en_us&edition=fundamental","pubTime":"2026-08-07 16:33","pubTimestamp":1786091580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. slipped 0.8% to 16.96 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.5% to 25668.03.This was the stock's fourth consecutive day of losses.Sinopharm Group Co. Ltd. closed 24% short of its 52-week high of HK$22.34, which the company achieved Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 4.0%.Trading volume totaled 2.4 million shares, compared to the 50-day average of 6.3 million shares.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0187","BK0188","BK0196","BK0096","BK1197","BK0028","BK1500","BK0060","BK1515","600196","02196","BK4175","BK0175","LU1115378108.SGD","SHTDY","BK1593","BK0183","BK0239","BK1191","01099","LU0640798160.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656737515","title":"Fosun Pharma Units Get Registration Nod for Two Drugs in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2656737515","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656737515?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:32","pubTimestamp":1785756726,"startTime":"0","endTime":"0","summary":"Two units of Shanghai Fosun Pharmaceutical's  obtained drug registration approval for certain products from China's National Medical Products Administration, according to two Monday Hong Kong bourse filings.Suzhou Erye Pharmaceutical's Polyethylene Glycol and Electrolytes Powder got approved for the indications of the treatment of chronic constipation in children aged one to 11 and fecal impaction in children from the age of five years.Separately, Fosun Wanbang  Pharmaceutical Group got a nod for Empagliflozin and Metformin Hydrochloride Sustained-release Tablets as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0188","BK1515","BK0060","BK0196","600196","02196","BK0239","BK0096","BK1593","BK1191","BK0012","BK0175","BK0187","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656273213","title":"Shanghai Fosun Pharma - Drug Registration Application for Empagliflozin & Metformin Hydrochloride Sustained-Release Tablets（Iii）Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2656273213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656273213?lang=en_us&edition=fundamental","pubTime":"2026-08-03 17:43","pubTimestamp":1785750196,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN43Y02E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0012","BK0187","BK0239","BK0188","BK0060","BK1191","BK0175","BK0196","BK1515","600196","BK0096","02196","BK1593","BK0183","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656015322","title":"Shanghai Fosun Pharma - Registration Application for Polyethylene Glycol (3350) and Electrolytes Powder Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2656015322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656015322?lang=en_us&edition=fundamental","pubTime":"2026-08-03 17:36","pubTimestamp":1785749761,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN4400P2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK0028","BK0175","600196","02196","BK0187","BK0196","BK0239","BK1593","BK0060","BK1191","BK0012","BK0096","BK0183","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111997866","title":"Shanghai Fosun Pharmaceutical Secures Regulatory Approval for Diabetes Combination Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1111997866","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111997866?lang=en_us&edition=fundamental","pubTime":"2026-08-03 16:40","pubTimestamp":1785746419,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) announced that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., has received regulatory approval from the National...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK0196","BK0028","BK1191","BK0187","BK1515","III","BK4134","BK0183","BK0060","BK0175","BK0188","02196","BK1593","BK0012","BK0096","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655946356","title":"Sinopharm Group Stock Falls 1.5% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2655946356","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655946356?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:33","pubTimestamp":1785486780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. slipped 1.5% to 17.38 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.1% to 25884.43.This was the stock's second consecutive day of losses.Sinopharm Group Co. Ltd. closed 22% below its 52-week high of HK$22.34, which the company achieved Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 0.3%.Trading volume totaled 5.9 million shares, compared to the 50-day average of 6.5 million shares.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0640798160.USD","BK1191","BK1593","BK0239","BK0187","LU1115378108.SGD","BK0175","600196","BK1197","BK0060","BK0196","BK1500","02196","BK0096","BK0028","BK0188","BK1515","BK0012","SHTDY","BK0183","01099","BK4175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655841132","title":"Fosun Pharma's Two Venture Capital Funds Complete Regulatory Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2655841132","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655841132?lang=en_us&edition=fundamental","pubTime":"2026-07-30 11:16","pubTimestamp":1785381366,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  said its two newly established venture capital funds have completed filing with the Asset Management Association of China, effective July 28.The Tianjin Phase II Fund, with a group investment of 29.8 million yuan, and the Hangzhou Fund, with a group investment of 27.8 million yuan, are both managed by Shanghai Fujian Equity Investment Fund Management.The funds aim to expand Shanghai Fosun Pharmaceutical's pipeline of early-stage innovative projects in pharmaceuticals and medical devices.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0012","BK0196","BK0239","BK0060","BK0183","BK0096","BK0187","BK0175","BK0188","BK0028","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199720089","title":"Fosun Pharma's investment fund successfully completes registration with securities authorities","url":"https://stock-news.laohu8.com/highlight/detail?id=1199720089","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199720089?lang=en_us&edition=fundamental","pubTime":"2026-07-29 17:56","pubTimestamp":1785318976,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) has announced that its participating investment funds have completed filing with the Asset Management Association of China.To expand channels for early-stage innovation project...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1515","BK0183","BK0096","BK0012","BK0060","BK0175","BK0187","600196","BK1191","BK0188","BK0028","02196","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655440863","title":"Fosun Expects 1H Profit Attributable to Owners at RMB 1.5 billion-RMB 1.8 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2655440863","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655440863?lang=en_us&edition=fundamental","pubTime":"2026-07-29 17:33","pubTimestamp":1785317595,"startTime":"0","endTime":"0","summary":"Fosun expects 1H profit attributable to owners at RMB 1.5 billion-RMB 1.8 billionFosun forecast 1H 2026 profit attributable to owners of RMB 1.5-1.8 billion, up about 127%-172% from a year earlier.Out","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDLCHHk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0096","BK4162","BK0239","600196","PRU","BK0187","BK0012","BK1230","BK0183","BK0175","601969","BK0060","00656","BK0196","BK0028","BK4585","BK0249","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655685012","title":"Sinopharm Group Stock Climbs 2.6% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2655685012","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655685012?lang=en_us&edition=fundamental","pubTime":"2026-07-29 16:33","pubTimestamp":1785313980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. rallied 2.6% to 17.70 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 2.0% to 25807.92.This was the stock's third consecutive day of gains.Sinopharm Group Co. Ltd. closed 21% below its 52-week high of HK$22.34, which the company reached Feb. 25.The stock outperformed some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 2.0%.Trading volume totaled 5.3 million shares, compared to the 50-day average of 6.5 million shares.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK0188","SHTDY","BK0012","BK0096","BK0183","BK0187","02196","BK0028","BK0239","01099","BK0196","BK1593","BK1191","BK1197","LU0640798160.USD","BK4175","BK0060","BK1500","LU1115378108.SGD","BK0175","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654054018","title":"Sinopharm Group Stock Climbs 2.0% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2654054018","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654054018?lang=en_us&edition=fundamental","pubTime":"2026-07-27 16:32","pubTimestamp":1785141120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. advanced 2.0% to 17.17 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.0% to 25207.18.The stock's rise snapped a four-day losing streak.Sinopharm Group Co. Ltd. closed 23% short of its 52-week high of HK$22.34, which the company achieved Feb. 25.The stock outperformed some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 0.8%.Trading volume totaled 4.8 million shares, compared to the 50-day average of 6.6 million shares.Data source: Dow Jones Market Data, FactSet Dow Jones NewswiresJuly 27, 2026 04:32 ET Copyright  2026 Dow Jones & Company, Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01099","BK0196","BK0096","LU0640798160.USD","BK1197","BK1500","BK0183","600196","SHTDY","BK1191","BK0028","BK0012","BK0175","02196","BK0187","BK0239","LU1115378108.SGD","BK1593","BK4175","BK0188","BK0060","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135683425","title":"Fosun Pharma Gains Approval for Clinical Trial of Parkinson's Disease Treatment DM1001","url":"https://stock-news.laohu8.com/highlight/detail?id=1135683425","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135683425?lang=en_us&edition=fundamental","pubTime":"2026-07-26 09:41","pubTimestamp":1785030095,"startTime":"0","endTime":"0","summary":"Fosun Pharma (02196) has announced that its subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., has received approval from the National Medical Products Administration to conduct...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196","BK1515","MDTX","IBBQ","BK1593","BK0196","BK0175","BK0096","BMED","PSYK","BK0187","BK0239","BK0183","BK0012","IBBJ","BK0060","BK1191","600196","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653088663","title":"Shanghai Fosun Pharma - Approval from National Medical Products Administration for Clinical Trial of Dm1001 Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2653088663","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653088663?lang=en_us&edition=fundamental","pubTime":"2026-07-24 17:18","pubTimestamp":1784884684,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nFWN43Q0MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0183","02196","600196","BK0239","BK0187","BK0012","BK1191","BK0096","BK0188","BK1593","BK0028","BK1515","BK0060","BK0175","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149585123","title":"Fosun Pharma Subsidiary Gains Green Light for DM1001 Drug Trial in Parkinson's Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1149585123","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149585123?lang=en_us&edition=fundamental","pubTime":"2026-07-24 16:52","pubTimestamp":1784883151,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (SHA: 600196) has announced that its controlled subsidiary, Fosun Universal (Jiangsu) Pharmaceutical Group Co., Ltd., has received approval from China's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0188","BK0196","IBBQ","IBBJ","BK1593","BK1515","BK0012","BK0028","BK0175","BK1191","BK0187","600196","BK0096","BK0239","BMED","MDTX","PSYK","BK0183","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653758736","title":"Sinopharm Group Stock Falls 1.9% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2653758736","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653758736?lang=en_us&edition=fundamental","pubTime":"2026-07-22 16:32","pubTimestamp":1784709120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. slipped 1.9% to 16.99 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.0% to 24892.66.This was the stock's second consecutive day of losses.Sinopharm Group Co. Ltd. closed 24% short of its 52-week high of HK$22.34, which the company reached Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 0.1%.Trading volume totaled 5.1 million shares, compared to the 50-day average of 6.6 million shares.Data source: Dow Jones Market Data, FactSet Dow Jones NewswiresJuly 22, 2026 04:32 ET Copyright  2026 Dow Jones & Company, Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","SHTDY","BK4175","BK0060","BK0028","BK0188","02196","BK1515","BK0239","BK0187","BK1191","LU1115378108.SGD","BK0012","600196","LU0640798160.USD","BK0175","BK1197","BK0096","BK1500","01099","BK0196","BK1593"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786440943860,"stockEarnings":[{"period":"1week","weight":0.0419},{"period":"1month","weight":0.0464},{"period":"3month","weight":-0.0309},{"period":"6month","weight":-0.0989},{"period":"1year","weight":-0.0695},{"period":"ytd","weight":-0.0737}],"compareEarnings":[{"period":"1week","weight":0.0412},{"period":"1month","weight":-0.0074},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.04},{"period":"1year","weight":0.0912},{"period":"ytd","weight":-0.0006}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","registeredCapital":"267042万元","survey":"　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。根据工信部中国医药工业信息中心颁布的“2024年度中国医药工业百强企业榜单”，本集团位列第5位。此外，在ESG方面，复星医药于报告期内荣登2025《财富》ESG影响力榜单，成为唯一入选该榜单的中国医药企业。根据MSCI于2025年7月公布的ESG年度评级结果，本集团MSCIESG评级提升至AA级。在AI领域，复星医药凭借自主研发的PharmAID医药智能平台荣获福布斯“2025中国人工智能科技创新场景应用企业TOP10”。","listedPrice":7.15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.,600196,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股价,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股市,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票价格,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票交易,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票购买,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction